MarketMoodz
FDA Warns Of Fatal Liver Risks Linked To Tavneos Use
The FDA cautioned about serious and sometimes fatal liver injuries tied to Tavneos (avacopan) based on postmarketing reports through October 9, 2024. The data extend beyond what was seen in clinical trials and could influence labeling, risk management, and Amgen’s sales outlook.
Key Takeaways
- 76 DILI cases linked to avacopan through Oct 9, 2024
- Among these, 74 were serious (54 hospitalizations, 8 deaths)
- 7 VBDS cases with 3 deaths; liver injury onset median 46 days (range 22–140) and VBDS onset median 46 days (range 33–59)
- Tavneos approved Oct 2021 for adults with severe active ANCA-associated vasculitis with glucocorticoids
- FDA will continue postmarketing monitoring; possible labeling updates and risk mitigation affecting sales
People Involved
- No specific individuals mentioned
Entities Involved
- Amgen Inc. (AMGN) Biotech company behind Tavneos (avacopan)
- Tavneos (avacopan) FDA-approved drug for adult ANCA-associated vasculitis
- U.S. Food and Drug Administration (FDA) Regulator issuing safety warning and ongoing postmarketing surveillance
MarketMoodz Analysis
For investors, the warning introduces regulatory risk that could cap Tavneos' growth and weigh on Amgen's near-term revenue. Depending on the severity and any labeling changes, sales could face headwinds, and the stock may exhibit heightened volatility.
Historically, postmarket safety signals have re-rated biotech assets when new risks emerge after approval, especially for rare-disease therapies with premium pricing. The current data—76 DILI cases with 74 serious outcomes and 7 VBDS cases—underscore the ongoing safety-monitoring dynamic that can influence investor expectations, pipeline valuation, and capital allocation.
What to watch next: look for any FDA labeling updates, REMS changes, or new safety communications; monitor Amgen's commentary, updated postmarketing reports, and quarterly results for signs of revenue impact or strategic pivots.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial